EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

Przemysław R Kac iD, Daniel Alcolea, Laia Montoliu-Gaya, Susana Fernández, Juan Lantero Rodriguez, Lucía Maure, Fernando González-Ortiz, Bessy Benejam, Michael Turton, Isabel Barroeta, Peter Harrison, Laura Videla und 7 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Przemysław R Kac und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, …. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, tau Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Instituto de Salud Carlos III, Kirsten og Freddy Johansens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND All individuals with Down syndrome (DS) will develop full‐blown Alzheimer´s disease (AD) pathology by age 40. Several genes encoded in chromosome 21, including dual‐specificity tyrosine phosphorylation‐regulated kinase 1A ( DYRK1A ), have been proven to contribute to the pathology. Phosphorylation of tau at threonine‐212 (p‐tau212) is very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. METHODS Using single molecule array (Simoa) technology, we tested p‐tau212 and p‐tau181 ( n = 245 for plasma, n = 114 matching cerebrospinal fluid [CSF] samples). RESULTS We have confirmed that the levels of plasma p‐tau212 are increased in the DS population and sporadic AD cases, including prodromal and mild cognitive impairment states. Plasma p‐tau212 started increasing approximately when people became amyloid positron emission tomography positive. DISCUSSION Plasma p‐tau212 might have utility for theragnostics, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD. Highlights Plasma p‐tau212 is increased in the Down syndrome (DS) population. Plasma p‐tau212 increases ≈15 years before the disease onset in DSAD. Plasma p‐tau212 accurately differentiates between control and disease groups. Plasma p‐tau212 accurately differentiates amyloid beta (Aβ)+ and Aβ− participants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeAlzheimer Diseasetau ProteinsHumansBiomarkersMaleFemalePhosphorylationMiddle AgedAgedPositron-Emission TomographyDyrk KinasesAdultCognitive DysfunctionAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer´s diseaseCSF biomarkersDABNIDYRK1ADown syndromeSPINSimoaplasma biomarkersp‐tau212

Substanzen

tau ProteinsBiomarkersDyrk KinasesMAPT protein, humanAmyloid beta-Peptides

Autor:innen und Institutionen

  • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
  • Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Av. Monforte de Lemos, Madrid, Spain.
  • Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Carrer del Comte Borrell, Barcelona, Spain.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Bioventix Plc, Farnham, UK.

ORCID-Profile: Przemysław R Kac

Förderung

  • NIA NIH HHS
  • Instituto de Salud Carlos III
  • Kirsten og Freddy Johansens Fond
  • Emil och Wera Cornells Stiftelse
  • HORIZON EUROPE Reforming and enhancing the European Research and Innovation system
  • NIH HHS
  • Vetenskapsrådet
  • Alzheimerfonden

Zitieren

APA

Kac, P. R., Alcolea, D., Montoliu-Gaya, L., Fernández, S., Rodriguez, J. L., Maure, L., González-Ortiz, F., Benejam, B., Turton, M., Barroeta, I., Harrison, P., Videla, L., Ashton, N. J., Lleó, A., Zetterberg, H., Carmona-Iragui, M., Karikari, T. K., Fortea, J., & Blennow, K. (2025). Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70172

Vancouver

Kac PR, Alcolea D, Montoliu-Gaya L, Fernández S, Rodriguez JL, Maure L, et al. Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70172

BibTeX
@article{Kac2025,
  author = {Kac, Przemysław R and Alcolea, Daniel and Montoliu-Gaya, Laia and Fernández, Susana and Rodriguez, Juan Lantero and Maure, Lucía and González-Ortiz, Fernando and Benejam, Bessy and Turton, Michael and Barroeta, Isabel and Harrison, Peter and Videla, Laura and Ashton, Nicholas J and Lleó, Alberto and Zetterberg, Henrik and Carmona-Iragui, María and Karikari, Thomas K and Fortea, Juan and Blennow, Kaj},
  title = {Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70172}
}
Kostenlos starten →